Biofrontera. Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
69
- Stock Symbol
-
B8FK
- Investments
-
2
- Share Price
-
$3.33
- (As of Thursday Closing)
Biofrontera. General Information
Description
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
Contact Information
Website
www.biofrontera.comCorporate Office
- Hemmelrather Weg 201
- 51377 Leverkusen
- Germany
Corporate Office
- Hemmelrather Weg 201
- 51377 Leverkusen
- Germany
Biofrontera. Stock Performance
As of 12-Nov-2026, Biofrontera.’s stock price is $3.33. Its current market cap is $20.2M with 6.08M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.33 | $3.36 | $2.52 - $5.84 | $20.2M | 6.08M | 1.46K | $1.01 |
Biofrontera. Financials Summary
As of 30-Jun-2026, Biofrontera. has a trailing 12-month revenue of $15.7M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 10,852 | 13,350 | 10,934 | 25,860 |
| Revenue | 15,708 | 14,877 | 13,183 | 34,896 |
| EBITDA | (834) | (632) | (397) | (1,452) |
| Net Income | 6,137 | (4,473) | (4,707) | (399) |
| Total Assets | 29,688 | 24,248 | 30,857 | 33,971 |
| Total Debt | 1,255 | 76 | 796 | 1,224 |
Biofrontera. Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biofrontera. Comparisons
Industry
Financing
Details
Biofrontera. Competitors (15)
One of Biofrontera.’s 15 competitors is Intas Pharmaceuticals, a Private Equity-Backed company based in Ahmedabad, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | ||||
| Beximco Pharmaceuticals | Corporation | Dhaka, Bangladesh | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Pil-psychotropics India | Corporation | Faridabad, India |
Biofrontera. Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biofrontera. Patents
Biofrontera. Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20070190043-A1 | Decreasing or inhabiting hyperproliferation of keratinocytes and/or t-cells ; cream; use treating psoriasis or atopic dermatitis for example | Inactive | 28-Apr-2003 | ||
| AU-2002316980-A1 | 1-methyl-4-(3-ethoxy-9h-thioxanthene-9-ylidene)-piperidine and its use as 5-ht2b and/or h1 antagonist | Inactive | 19-Jun-2001 | ||
| WO-2002102797-A1 | 1-methyl-4-(3-ethoxy-9h-thioxanthene-9-ylidene)-piperidine and its use as 5-ht2b and/or h1 antagonist | Inactive | 19-Jun-2001 | C07D409/04 |
Biofrontera. Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biofrontera. Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biofrontera. Acquisitions (2)
Biofrontera.’s most recent deal was a Merger/Acquisition with Cutanea Life Sciences. The deal was made on 25-Mar-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cutanea Life Sciences | 25-Mar-2019 | Merger/Acquisition | Drug Discovery | ||
| Allergan (Ameluz & BF-RhodoLED Distribution) | 07-Nov-2014 | Merger/Acquisition | Drug Delivery |
Biofrontera. ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Biofrontera. FAQs
-
When was Biofrontera. founded?
Biofrontera. was founded in 1997.
-
Where is Biofrontera. headquartered?
Biofrontera. is headquartered in Leverkusen, Germany.
-
What is the size of Biofrontera.?
Biofrontera. has 69 total employees.
-
What industry is Biofrontera. in?
Biofrontera.’s primary industry is Pharmaceuticals.
-
Is Biofrontera. a private or public company?
Biofrontera. is a Public company.
-
What is Biofrontera.’s stock symbol?
The ticker symbol for Biofrontera. is B8FK.
-
What is the current stock price of Biofrontera.?
As of 12-Nov-2026 the stock price of Biofrontera. is $3.33.
-
What is the current market cap of Biofrontera.?
The current market capitalization of Biofrontera. is $20.2M.
-
What is Biofrontera.’s current revenue?
The trailing twelve month revenue for Biofrontera. is $15.7M.
-
Who are Biofrontera.’s competitors?
Intas Pharmaceuticals, Beximco Pharmaceuticals, Pfizer (Vienna), Genentech, and Pil-psychotropics India are some of the 15 competitors of Biofrontera..
-
What is Biofrontera.’s annual earnings per share (EPS)?
Biofrontera.’s EPS for 12 months was $1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
